Lyell Immunopharma (LYEL) stock: insider trades, news & valuation
Net buyingShare price and insider trades
Lyell Immunopharma insider trading at a glance (Oct 9, 2026): in the past 12 months, 2 insiders bought $25.0M and 6 sold $605K of LYEL stock on the open market.
Get emailed when insiders cluster-buy stocks like LYEL
Free alerts the day a new cluster buy is filed, plus the Monday report of the week's biggest insider trades.
Free · unsubscribe anytime · not investment advice · see a sample issue
LYEL insider buying and selling by quarter
Open-market purchases (green, above the line) and sales (red, below), by trade date.
| Quarter | Bought | Purchases | Sold | Sales |
|---|---|---|---|---|
| Q4 2026 | — | 0 | — | 0 |
| Q3 2026 | — | 0 | $211K | 10 |
| Q2 2026 | — | 0 | $41K | 5 |
| Q1 2026 | $25.0M | 2 | $264K | 7 |
| Q4 2025 | — | 0 | $88K | 6 |
Valuation, profit and volume
Summary
Over the past 12 months, 2 Lyell Immunopharma, Inc. insiders reported open-market purchases totaling $25.0M, while 6 insiders reported sales totaling $605K. Among insiders with enough purchase history to measure, Paul L Berns (10% Owner) has the highest Insider Score at 4. 2 of 28 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.
Insider transactions
Open-market purchases and sales.
| Filed | Insider | Type | Shares | Price | Value | Since | Score |
|---|---|---|---|---|---|---|---|
| Sep 10SEC | David ShookChief Medical Officer | Sell | 50020,423 held (−2%) | $12.70 | $6K | -31.4% | — |
| Aug 25SEC | Lynn SeelyCEO, President | Sell | 9,58963,899 held (−13%) | $15.54 | $149K | -44.0% | — |
| Aug 25SEC | Gary K. LeeChief Scientific Officer | Sell | 1,45716,220 held (−8%) | $15.54 | $23K | -44.0% | — |
| Aug 25SEC | Stephen J. HillCOO | Sell | 98916,816 held (−6%) | $15.54 | $15K | -44.0% | — |
| Aug 11SEC | Veronica Sanchez BulisVp, Corporate Controller | Sell | 62114,799 held (−4%) | $14.34 | $9K | -39.3% | — |
| Aug 11SEC | Lynn SeelyCEO, President | Sell | 39073,488 held (−1%) | $14.34 | $6K | -39.3% | — |
| Aug 11SEC | Gary K. LeeChief Scientific Officer | Sell | 13117,677 held (−1%) | $14.34 | $2K | -39.3% | — |
| Aug 11SEC | Stephen J. HillCOO | Sell | 8917,805 held (−0%) | $14.34 | $1K | -39.3% | — |
| Jul 20SEC | Innovative Cellular Therapeutics Holdings Ltd10% Owner | Sell Plan | 102,857,480 held (−0%) | $13.70 | $137 | -36.4% | — |
| Jul 17SEC | Innovative Cellular Therapeutics Holdings Ltd10% Owner | Sell Plan | 102,857,490 held (−0%) | $13.73 | $137 | -36.6% | — |
| Jun 15SEC | Lynn SeelyCEO, President | Sell | 38873,878 held (−1%) | $18.91 | $7K | -53.9% | — |
| Jun 15SEC | Veronica Sanchez BulisVp, Corporate Controller | Sell | 21715,420 held (−1%) | $18.91 | $4K | -53.9% | — |
| Jun 15SEC | Gary K. LeeChief Scientific Officer | Sell | 13017,808 held (−1%) | $18.92 | $2K | -54.0% | — |
| Jun 15SEC | Stephen J. HillCOO | Sell | 8917,894 held (−0%) | $18.92 | $2K | -54.0% | — |
| Jun 11SEC | David ShookChief Medical Officer | Sell | 1,97720,923 held (−9%) | $12.64 | $25K | -31.1% | — |
| Mar 9SEC | Paul L Berns10% Owner | Buy | 488,0901,426,528 held (+52%) | $25.61 | $12.5M | -66.0% | 4 |
| Mar 9SEC | Arch Venture Partners Ix Overage, L.P.10% Owner | Buy | 488,0901,426,528 held (+52%) | $25.61 | $12.5M | -66.0% | — |
| Feb 12SEC | Lynn SeelyCEO, President | Sell | 7,45574,266 held (−9%) | $23.39 | $174K | -62.8% | — |
| Feb 12SEC | Gary K. LeeChief Scientific Officer | Sell | 1,67116,938 held (−9%) | $23.39 | $39K | -62.8% | — |
| Feb 12SEC | Stephen J. HillCOO | Sell | 1,23617,795 held (−6%) | $23.39 | $29K | -62.8% | — |
| Feb 11SEC | Lynn SeelyCEO, President | Sell | 43881,721 held (−1%) | $23.12 | $10K | -62.3% | — |
| Feb 11SEC | Veronica Sanchez BulisVp, Corporate Controller | Sell | 25415,637 held (−2%) | $23.12 | $6K | -62.3% | — |
| Feb 11SEC | Gary K. LeeChief Scientific Officer | Sell | 14718,609 held (−1%) | $23.12 | $3K | -62.3% | — |
| Feb 11SEC | Stephen J. HillCOO | Sell | 10919,031 held (−1%) | $23.12 | $3K | -62.3% | — |
| Jan 6SEC | Veronica Sanchez BulisVp, Corporate Controller | Sell | 1,1368,077 held (−12%) | $38.67 | $44K | -77.5% | — |
| Jan 6SEC | Veronica Sanchez BulisVp, Corporate Controller | Sell | 9367,141 held (−12%) | $32.32 | $30K | -73.1% | — |
| Nov 12SEC | Lynn SeelyCEO, President | Sell | 41267,159 held (−1%) | $16.11 | $7K | -45.9% | — |
| Nov 12SEC | Veronica Sanchez BulisVp, Corporate Controller | Sell | 2399,213 held (−3%) | $16.10 | $4K | -45.9% | — |
| Nov 12SEC | Gary K. LeeChief Scientific Officer | Sell | 13815,366 held (−1%) | $16.16 | $2K | -46.1% | — |
| Nov 12SEC | Stephen J. HillCOO | Sell | 9515,750 held (−1%) | $16.12 | $2K | -46.0% | — |
Insiders at Lyell Immunopharma, Inc.
| Insider | Bought | Sold | Last filing | Score |
|---|---|---|---|---|
| Paul L Berns10% Owner | $12.5M | — | Mar 9, 2026 | 4 |
| Arch Venture Partners Ix Overage, L.P.10% Owner | $12.5M | — | Mar 9, 2026 | — |
| Lynn SeelyCEO, President | — | $353K | Aug 25, 2026 | — |
| Veronica Sanchez BulisVp, Corporate Controller | — | $97K | Aug 11, 2026 | — |
| Gary K. LeeChief Scientific Officer | — | $72K | Aug 25, 2026 | — |
| Stephen J. HillCOO | — | $51K | Aug 25, 2026 | — |
| David ShookChief Medical Officer | — | $31K | Sep 10, 2026 | — |
| Innovative Cellular Therapeutics Holdings Ltd10% Owner | — | $274 | Jul 20, 2026 | — |
LYEL stock: common questions
Are Lyell Immunopharma, Inc. insiders buying LYEL stock?
In the past 12 months, 2 insiders reported open-market purchases of LYEL worth $25.0M. The latest was 10% Owner Paul L Berns bought $12.5M of LYEL at $25.61 — first open-market purchase in our records; raises the stake by 52%.
Are Lyell Immunopharma, Inc. insiders selling LYEL stock?
6 insiders reported sales worth $605K over the same period.
Where does this data come from?
Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.
What is LYEL's 52-week range?
Over the past year LYEL has traded between $8.56 and $38.60. It last closed at $8.71 on Oct 9, 2026.